Details of the Drug Combinations

General Information of This Drug (ID: DMHFTD0)

Drug Name

Y-700 DMHFTD0

Synonyms

niraxostat; Piraxostat; Y-700; UNII-246FR6022S; CHEMBL169526; 206884-98-2; 1-[3-CYANO-4-(NEOPENTYLOXY)PHENYL]-1H-PYRAZOLE-4-CARBOXYLIC ACID; 246FR6022S; YSH; 1-(3-cyano-4-neopentyloxyphenyl) pyrazole-4-carboxylic acid; 1-[3-cyano-4-(2,2-dimethylpropoxy)phenyl]-1h-pyrazole-4-carboxylic acid; Niraxostat [INN]; Y 700; AC1L9MN7; MLS006010327; SCHEMBL440021; ZINC7343; DTXSID70174747; AETHRPHBGJAIBT-UHFFFAOYSA-N; MolPort-005-943-250; BDBM50098068; DB03841; NCGC00263135-01; ACM206884982; SMR004701391; FT-0728443

Indication

Disease Entry	ICD 11	Status	REF
Gout	FA25	Discontinued in Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Y-700 + Mitomycin	DCE1RP7	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010582)
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.